Ophthalmology Therapeutics Market Report

Global Ophthalmology Therapeutics Market Size 

The Global Ophthalmology Therapeutics Market is projected to grow from USD 34.21 billion in 2025 to USD 36.74 billion in 2026 and reach USD 65.04 billion by 2034, registering a CAGR of 7.4% from 2026 to 2034.

Ophthalmology is a medicine and surgical branch that deals with diagnosing and treating eye disorders, using laser therapies and medications to perform surgeries. As per the World Health Organization (2019, it is estimated that 2.2 billion people are visually impaired, over 39 million people have lost their vision, approximately 188.5 million have mild vision impairment, and above 217 million people have been experiencing moderate to severe vision impairment. In addition, eye care has become costly, with the consistent rise in the widespread ophthalmologic diseases worldwide, the increasing cost of treatment, and the rising need for ophthalmology.

MARKET DRIVERS

The global ophthalmology therapeutics market showcases evident potential in the mentioned forecasting period.

Ophthalmology is the branch of medicine associated with treating eye defects and diseases. With the recent advancements in genetics and stem cell biology, the mechanisms of many ophthalmic diseases are being revealed progressively.The growing prevalence of ophthalmic diseases and the rising need for cost-effective ophthalmic disease therapeutics drive the growth of the ophthalmology therapeutics market.

An increase in presbyopia, macular degeneration, and diabetic retinopathy is the market's primary driver. Furthermore, the ophthalmic disease market is expected to accelerate due to the increase in research & development activities and investment funding by the government and various private organizations to improve the healthcare infrastructure. In addition, the introduction of ophthalmic devices, advanced technologies, and people in emerging countries opting for ophthalmic surgeries to correct their eye-related problems are further expected to propel the market growth. 

The global market for ophthalmology therapeutics is further driven by the growing prevalence of vision impairment, estimated to be 147 million in 2010. It is estimated to reach 191 million in the world in 2020. Technological advancement in medicine also plays a significant role in the market's growth. Increasing the geriatric population worldwide and rising disposable income are other factors driving the global ophthalmology therapeutics market.

MARKET RESTRAINTS

Lack of awareness regarding the various diseases associated with ophthalmology is a major factor restraining the market's growth.

Stringent regulatory frameworks and unclear reimbursement policies are hurdles to market growth. Lack of awareness in rural areas about the various ophthalmic disorders and lack of health insurance covering all types of IOLs and contact lenses are restraining the market growth. Vision care has become costly; many people in all parts of the world cannot afford ophthalmic treatments. This is considered the primary factor for the declining global ophthalmology therapeutics market growth. 

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Basis of Indication Insights

Based on indication, the glaucoma segment is the most significant indication segment, accounting for approximately 31%, followed by AMD, with a share of 27%. Also, the retinal vein Occlusion segment held the largest market share in 2019. It dominated the market share owing to the increased prevalence of age-related macular degeneration. Pipeline candidates working on VEGF inhibition principles will drive the segment growth during the forecast period.

By End User Insights

Based on the end-user, eye clinics and hospitals lead the market during the forecast period. The increasing prevalence of eye-related problems and the rising need for cost-effective ophthalmic disease therapeutics drive market growth.

REGIONAL ANALYSIS

Geographically, North America dominated the global ophthalmology therapeutics market in 2023, followed by Europe. Asia-Pacific is estimated to be the fastest-growing region during the forecast period. The domination of the North American market is attributed to increasing awareness among people about the benefits of ophthalmic drugs, and technological advancements have increased. Moreover, government measures and increased investments to improve the healthcare infrastructure propel market growth over the forecast period.

The European market held the second-largest share in the global ophthalmology therapeutics market in 2023. Increasing investments by the government and advancing healthcare infrastructure facilities are propelling the market. 

Asia Pacific is anticipated to grow at a healthy CAGR over the forecast period. Factors such as rising disposable income, improving economic scenario, and the large patient pool are fuelling the market demand. In addition, the increasing introduction of new product launches is boosting the market growth over the years. 

Middle East & Africa is expected to record a moderate share in the coming years. The increasing patient pool and rise in the prevalence of presbyopia are boosting the market growth in this region.

KEY MARKET PLAYERS 

Some of the most prominent companies leading the global ophthalmology therapeutics market profiled in the report are Pfizer Inc., Allergan Inc., Alcon Inc., Merck & Co. Inc., Roche Valeant, Regeneron, Santen, Bayer, Senju, Lpath, and Eye Gate Pharmaceuticals.

RECENT HAPPENINGS IN THIS MARKET

• In December 2020, Eye Gate Pharmaceuticals, a clinical-stage company focused on developing products to treat the eye.  

MARKET SEGMENTATION

This research report on the global ophthalmology therapeutics market has been segmented and sub-segmented based on the indication, end-user, and region.

By Basis of Indication

• Glaucoma
• Dry Eye Syndrome
• Diabetic Retinopathy
• Retinal Vein Occlusion
• Age-related Macular Degeneration
• Macular Edema
• Allergic Conjunctivitis

By End User

• Hospitals
• Eye Clinics
• Diagnostic Centres
• Patients

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa